Apr. 15, 2014
The biotechnology company Mucosis B.V. announced on April 15, 2014 that it entered into a long-term collaboration and license agreement with China-based Changchun BCHT Biotechnology and raised EUR 5 million, in a new financing round.
Under the agreement with BCHT, Mucosis will receive an equity investment along with customary payments including royalties in return for a license to its SynGEM® prefusion F vaccine candidate for prevention of RSV. It will also receive a license for the Mimopath® platform for other disease targets. The license will be exclusive within the People’s Republic of China and non-exclusive in certain other Asian countries. Further details of the agreement were not disclosed.